Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 2627)

VOLUNTARY ANNOUNCEMENT
IND APPROVAL BY CHINA CDE FOR TETANUS TOXOID ADSORBED VACCINE

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the "**Company**" or "**Ab&B Bio-Tech**", together with its subsidiary, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that the Center for Drug Evaluation of the National Medical Products Administration (the "**China CDE**") has approved the Investigational New Drug (the "**IND**") application of the Group's self-developed tetanus toxoid adsorbed vaccine ("**Adsorbed Tetanus Vaccine**") candidate on November 12, 2026.

Tetanus is an acute specific infection caused by the entry of spores of the bacterium *clostridium tetani* into the body through wounds. It can be very dangerous and even fatal. The spores are found everywhere in the environment, particularly in soil, ash, feces of animals and humans, and on the surfaces of skin and rusty tools like nails, needles and barbed wire. The prevention of tetanus critically relies on both proper wound management and immunization. Primary prevention through active immunization involves the administration of vaccines containing tetanus toxoid to foster long-term immunity, while secondary prevention utilizes passive immunization techniques, introducing immediate immune effectors such as tetanus antitoxin (TAT) or immunoglobulin for acute cases. The Group's Adsorbed Tetanus Vaccine candidate aims to induce the production of protective antitoxin antibodies upon immunization. The Board considers that the approval of the IND application by the China CDE marks a significant advancement in the Group's research and development in the field of traditional vaccines and lays the foundation for the commencement of clinical studies of the candidate product.

About Ab&B Bio-Tech

Ab&B Bio-Tech is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. In formulating our pipeline, we closely track global trends in infectious disease incidence and vaccine R&D, with a strategic focus on premium vaccines, aiming to replace traditional vaccines and imported vaccines in China and establish our presence in international markets. Our range of products include but are not limited to, the quadrivalent subunit influenza vaccine, the trivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with other vaccine candidates.

Continued Suspension of Trading

Trading in the H Shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 and will remain suspended until further notice.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, chairman of our Board and general manager

Hong Kong, November 13, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Mr. HE Yiming as executive Directors; (ii) Mr. DU Mu as non-executive Director; and (iii) Mr. LI Xiangming, Mr. LI Jianjun, Mr. CHEN Chengbei and Ms. LUI Mei Ka as independent non-executive Directors.